Drug Interactions
Abiraterone Interactions
Acetylsalicylic acid
No clinically significant drug interactions identified.
Alprazolam
No clinically significant drug interactions identified.
Amitriptyline
Caution - increased level of amitriptyline due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Amlodipine
No clinically significant drug interactions identified.
Amoxicillin
No clinically significant drug interactions identified.
Amoxicillin/clavulanate
No clinically significant drug interactions identified.
Apixaban
Avoid combination - increased level of apixaban due to enzyme inhibition. Choose an alternative agent.
Atenolol
No clinically significant drug interactions identified.
Atorvastatin
Caution - increased level of atorvastatin due to OAT1B1 inhibition. Monitor for signs of toxicity (ie. CK). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction.
Azithromycin
No clinically significant drug interactions identified.
Bisoprolol
No clinically significant drug interactions identified.
Canagliflozin
No clinically significant drug interactions identified.
Candesartan
No clinically significant drug interactions identified.
Carbamazepine
Avoid combination - decreased level of abiraterone due to 3A4 induction. Choose an alternative agent.
Carvedilol
Caution - increased level of carvedilol due to 2D6 inhibition. Monitor for signs of toxicity (ie. hypotension, bradycardia, impotence). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Chlorthalidone
No clinically significant drug interactions identified.
Ciprofloxacin
No clinically significant drug interactions identified.
Citalopram
No clinically significant drug interactions identified.
Clarithromycin
No clinically significant drug interactions identified.
Clomipramine
Caution - increased level of clomipramine due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Clonazepam
No clinically significant drug interactions identified.
Clopidogrel
No clinically significant drug interactions identified.
Codeine
Caution - decreased level of codeine due to 2D6 inhibition. CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. Titrate with extreme caution due to risk of overdose. If already established on codeine, may require dose reduction. Consider choosing an alternative agent.
Dabigatran
Caution - increased level of dabigatran due to Pgp inhibition. Monitor for signs of bleeding. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Dapagliflozin
No clinically significant drug interactions identified.
Degarelix
No clinically significant drug interactions identified.
Desipramine
Caution - increased level of desipramine due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Dexamethasone
No clinically significant drug interactions identified.
Dexlansoprazole
No clinically significant drug interactions identified.
Diltiazem
No clinically significant drug interactions identified.
Doxycycline
No clinically significant drug interactions identified.
Duloxetine
Caution - increased level of duloxetine due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Dutasteride
No clinically significant drug interactions identified.
Edoxaban
Caution - increased level of edoxaban due to Pgp inhibition. Monitor for signs of bleeding. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Empagliflozin
No clinically significant drug interactions identified.
Escitalopram
No clinically significant drug interactions identified.
Esomeprazole
No clinically significant drug interactions identified.
Famotidine
No clinically significant drug interactions identified.
Finasteride
No clinically significant drug interactions identified.
Fluconazole
No clinically significant drug interactions identified.
Fluoxetine
No clinically significant drug interactions identified.
Furosemide
No clinically significant drug interactions identified.
Gabapentin
No clinically significant drug interactions identified.
Gliclazide
No clinically significant drug interactions identified.
Glyburide
No clinically significant drug interactions identified.
Goserelin
No clinically significant drug interactions identified.
Hydrochlorothiazide
No clinically significant drug interactions identified.
Hydromorphone
No clinically significant drug interactions identified.
Ibuprofen
No clinically significant drug interactions identified.
Irbesartan
No clinically significant drug interactions identified.
Lansoprazole
No clinically significant drug interactions identified.
Leuprolide
No clinically significant drug interactions identified.
Levofloxacin
No clinically significant drug interactions identified.
Levothyroxine
No clinically significant drug interactions identified.
Lorazepam
No clinically significant drug interactions identified.
Metformin
No clinically significant drug interactions identified.
Methadone
Caution - increased level of methadone due to 2D6 inhibition. Titrate with extreme caution due to risk of overdose. If already established on methadone, may require dose reduction. Consider choosing an alternative agent.
Metoclopramide
Caution - increased level of metoclopramide due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Metoprolol
Caution - increased level of metoprolol due to 2D6 inhibition. Monitor for signs of toxicity (ie. hypotension, bradycardia, impotence). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Mirabegron
No clinically significant drug interactions identified.
Mirtazapine
No clinically significant drug interactions identified.
Moxifloxacin
No clinically significant drug interactions identified.
Naproxen
No clinically significant drug interactions identified.
Nifedipine XL
No clinically significant drug interactions identified.
Nirapirib
No clinically significant drug interactions identified.
Nortriptyline
Caution - increased level of nortriptyline due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Olanzapine
No clinically significant drug interactions identified.
Olaparib
No clinically significant drug interactions identified.
Omeprazole
No clinically significant drug interactions identified.
Ondansetron
No clinically significant drug interactions identified.
Oxybutynin
No clinically significant drug interactions identified.
Oxycodone
Caution - increased level of oxycodone due to 2D6 inhibition. Titrate with extreme caution due to risk of overdose. If already established on oxycodone, may require dose reduction. Consider choosing an alternative agent.
Pantoprazole
No clinically significant drug interactions identified.
Paroxetine
Caution - increased level of paroxetine due to 2D6 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Perinodopril
No clinically significant drug interactions identified.
Phenytoin
Avoid combination - decreased level of abiraterone due to 3A4 induction. Choose an alternative agent.
Prednisone
No clinically significant drug interactions identified.
Pregabalin
No clinically significant drug interactions identified.
Prochlorperazine
No clinically significant drug interactions identified.
Quetiapine
No clinically significant drug interactions identified.
Rabeprazole
No clinically significant drug interactions identified.
Ramipril
No clinically significant drug interactions identified.
Ranitidine
No clinically significant drug interactions identified.
Risperidone
Caution - increased level of risperidone due to 2D6 inhibition. Monitor for signs of toxicity (ie. EPS, hyperprolactinemia). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Rivaroxaban
Avoid combination - increased level of rivaroxaban due to enzyme inhibition. Choose an alternative agent.
Rosuvastatin
Caution - increased level of rosuvastatin due to OAT1B1 inhibition. Monitor for signs of toxicity (ie. CK). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction.
Semaglutide
No clinically significant drug interactions identified.
Sertraline
No clinically significant drug interactions identified.
Sildenafil
No clinically significant drug interactions identified.
Silodosin
No clinically significant drug interactions identified.
Simvastatin
Caution - increased level of simvastatin due to OAT1B1 inhibition. Monitor for signs of toxicity (ie. CK). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction.
Sitagliptin
No clinically significant drug interactions identified.
Sulfamethoxazole-trimethoprim
No clinically significant drug interactions identified.
Tadalafil
No clinically significant drug interactions identified.
Talazoparib
No clinically significant drug interactions identified.
Tamsulosin
Caution - increased level of tamsulosin due to 2D6 inhibition. Monitor for signs of toxicity (ie. syncope). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Terazocin
No clinically significant drug interactions identified.
Ticagrelor
No clinically significant drug interactions identified.
Tolterodine
No clinically significant drug interactions identified.
Tramadol
Caution - increased level of tramadol due to 2D6 inhibition. Titrate with extreme caution due to risk of overdose. If already established on tramadol, may require dose reduction. Consider choosing an alternative agent.
